Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Strategies for reducing excess body fat... - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

Reclaim the Lives of Lupus Patients, A Unique Treatment Approach - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)

PTSD and other mental health treatment with opioid antagonist... - Galyn Forster, MS, LPC (2021 Conference) (LDN, low dose naltrexone)

Multiple Sclerosis - The role of combination therapy of LDN and Testosterone ... - Harpal Bains, MD (2021 Conference) (LDN, low dose naltrexone)

Eosinophilic Esophagitis Is More Treatable Than You Think - Deanna Windham, DO (2021 Conference) (LDN, low dose naltrexone)

Cooling the fire of lichen planopilaris - Apple Bodemer, MD (2021 Conference) (LDN, low dose naltrexone)

Cancer Case Studies - Akbar Khan, MD (2021 Conference) (LDN, low dose naltrexone)

Cancer is a systemic disease. This presentation is on using low dose naltrexone (LDN) as a cancer treatment, looking at several case reports, diagnostic tests, and various therapies. Cases include breast cancer, nodular melanoma, and adenocarcinoma with lymphovascular invasion in a colonic polyp